Skip to main content
Article
Licensed
Unlicensed Requires Authentication

Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy?

  • EMAIL logo , and
Published/Copyright: November 27, 2025
Journal of Basic and Clinical Physiology and Pharmacology
From the journal Journal of Basic and Clinical Physiology and Pharmacology Volume 37 Issue 1

Abstract

Mirikizumab is a monoclonal antibody that targets the human IL-23p19 and has been humanized with IgG4. It is currently under development for treating Crohn’s disease and ulcerative colitis. The FDA approved mirikizumab on October 26, 2023 as a highly effective treatment for ulcerative colitis, providing patients with a new option for this chronic and debilitating inflammatory bowel disease. Millions of people worldwide suffer from ulcerative colitis, and it is crucial to induce and maintain remission. However, existing therapies may not suffice in terms of efficacy or patient tolerability. Mirikizumab demonstrated a favorable safety profile during trials, with reported adverse events aligning with anticipated outcomes in the patient group. These safety results underscore the viability of mirikizumab as a well-tolerated therapeutic option for extended use. The trials data indicated that the treatment not only swiftly alleviated symptoms but also exhibited potential for sustaining remission over an extended period. This article seeks to offer a condensed overview of the noteworthy clinical trial outcomes that contributed to the development of mirikizumab, ultimately leading to its initial approval for the treatment of ulcerative colitis.

Keywords: ulcerative colitis; mirikizumab; cytokines; monoclonal antibody
Corresponding author: Dr. Saurav Misra, MBBS, MD, Assistant professor, Department of Pharmacology, Kalpana Chawla Government Medical College, Karnal, Haryana, India, E-mail:

  1. Research ethics: Since it is a review article (N/A), IEC permission was exempted/not required.

  2. Informed consent: Since it is a review article (N/A), Informed consent was exempted/not required.

  3. Author contributions: Dr Manmeet Kaur- Writing the article, editing, Dr Ashish Kumar Saranjhna- Writing the article, editing, Dr Saurav Misra- Idea, Concept, Writing the article, final editing, review, Submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: No.

  5. Conflict of interest: None.

  6. Research funding: None.

  7. Data availability: Yes within the manuscript.

References

1. Gajendran, M, Loganathan, P, Jimenez, G, Catinella, AP, Ng, N, Umapathy, C, et al.. A comprehensive review and update on ulcerative colitis. Dis Mon 2019;65:100851. https://doi.org/10.1016/j.disamonth.2019.02.004.Search in Google Scholar PubMed

2. Lynch, WD, Hsu, R. Ulcerative colitis. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459282/.Search in Google Scholar

3. Feuerstein, JD, Moss, AC, Farraye, FA. Ulcerative colitis. Mayo Clin Proc 2019; 94: 1357–73. https://doi.org/10.1016/j.mayocp.2019.01.018.Search in Google Scholar PubMed

4. Ashton, JJ, Ennis, S, Beattie, RM. Early-onset paediatric inflammatory bowel disease. Lancet Child Adolesc Health 2017;1:147–58.https://doi.org/10.1016/s2352-4642(17)30017-2.Search in Google Scholar

5. Liu, CY, Polk, DB. Microbiomes through the looking glass: what do UC? Cell Host Microbe 2018;24:472–4. https://doi.org/10.1016/j.chom.2018.09.013.Search in Google Scholar PubMed

6. Gradel, KO, Nielsen, HL, Schønheyder, HC, Ejlertsen, T, Kristensen, B, Nielsen, H. Increased short- and long-term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology 2009;137:495–501. https://doi.org/10.1053/j.gastro.2009.04.001.Search in Google Scholar PubMed

7. Guardiola, J, Lobatón, T, Cerrillo, E, Ferreiro-Iglesias, R, Gisbert, JP, Domènech, E, et al.. Recommendations of the Spanish working group on Crohn’s disease and ulcerative colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol 2018;41:514–29. https://doi.org/10.1016/j.gastrohep.2018.05.029.Search in Google Scholar PubMed

8. Lee, JS, Kim, ES, Moon, W. Chronological review of endoscopic indices in inflammatory bowel disease. Clin Endosc 2019;52:129–36. https://doi.org/10.5946/ce.2018.042.Search in Google Scholar PubMed PubMed Central

9. Meier, J, Sturm, A. Current treatment of ulcerative colitis. World J Gastroenterol 2011;17:3204–12. https://doi.org/10.3748/wjg.v17.i27.3204.Search in Google Scholar PubMed PubMed Central

10. Ferretti, F, Cannatelli, R, Monico, MC, Maconi, G, Ardizzone, S. An update on current pharmacotherapeutic options for the treatment of ulcerative colitis. J Clin Med 2022;11:2302. https://doi.org/10.3390/jcm11092302.Search in Google Scholar PubMed PubMed Central

11. Ungaro, R, Mehandru, S, Allen, PB, Peyrin-Biroulet, L, Colombel, JF. Ulcerative colitis. Lancet 2017;389:1756–70. https://doi.org/10.1016/s0140-6736(16)32126-2.Search in Google Scholar PubMed PubMed Central

12. Croxford, AL, Mair, F, Becher, B. IL-23: one cytokine in control of autoimmunity. Eur J Immunol 2012;42:2263–73. https://doi.org/10.1002/eji.201242598.Search in Google Scholar PubMed

13. Croxford, AL, Kulig, P, Becher, B. IL-12-and IL-23 in health and disease. Cytokine Growth Factor Rev 2014;25:415–21. https://doi.org/10.1016/j.cytogfr.2014.07.017.Search in Google Scholar PubMed

14. Gheita, TA, El Gazzar, II, El-Fishawy, HS, Aboul-Ezz, MA, Kenawy, SA. Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: preliminary results. Clin Rheumatol 2014;33:713–7. https://doi.org/10.1007/s10067-013-2469-y.Search in Google Scholar PubMed

15. Globig, AM, Hennecke, N, Martin, B, Seidl, M, Ruf, G, Hasselblatt, P, et al.. Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease. Inflamm Bowel Dis 2014;20:2321–9. https://doi.org/10.1097/mib.0000000000000210.Search in Google Scholar PubMed

16. El-Bassat, H, AboAli, L, El Yamany, S, Al Shenawy, H, Al Din, RA, Taha, A. Interleukin-23p19 expression in patients with ulcerative colitis and its relation to disease severity. Adv Digest Med 2016;3:88–94. https://doi.org/10.1016/j.aidm.2015.04.002.Search in Google Scholar

17. Food and drug administration (FDA) [Home page in internet] FDA Approved Drug Products: Omvoh (mirikizumab-mrkz) injection for intravenous or subcutaneous administration [Last cited on 22/11/2025] Available from: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class#:∼:text=Omvoh%20(mirikizumab%2Dmrkz%20is,inhibits%20the%20IL%2D23%20pathway.Search in Google Scholar

18. Drug, bank. [Home page in internet] Mirikizumab [Last cited on 22/11/2025] Available from: https://go.drugbank.com/drugs/DB14910.Search in Google Scholar

19. European Medicines agency (EMA) [Home page in internet] Committee for Medicinal Products for Human Use (CHMP) Summary of Positive Opinion: Omvoh (mirikizumab) [Last cited on 22/11/2025] Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-omvoh_en.pdf.Search in Google Scholar

20. Steere, B, Beidler, C, Martin, A, Bright, S, Kikly, K, Benschop, RJ. Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23. J Pharmacol Exp Therapeut 2023;387:180–7. https://doi.org/10.1124/jpet.122.001512.Search in Google Scholar PubMed

21. Sands, BE, Peyrin-Biroulet, L, Kierkus, J, Higgins, PDR, Fischer, M, Jairath, V, et al.. Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with crohn’s disease. Gastroenterology 2022;162:495–508. https://doi.org/10.1053/j.gastro.2021.10.050.Search in Google Scholar PubMed

22. Sandborn, WJ, Ferrante, M, Bhandari, BR, Berliba, E, Hibi, T, D’Haens, GR, et al.. Efficacy and safety of continued treatment with Mirikizumab in a phase 2 trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol 2022;20:105–15.e14. https://doi.org/10.1016/j.cgh.2020.09.028.Search in Google Scholar PubMed

23. Sandborn, WJ, Ferrante, M, Bhandari, BR, Berliba, E, Feagan, BG, Hibi, T, et al.. Efficacy and safety of Mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology 2020;158:537–49.e10. https://doi.org/10.1053/j.gastro.2019.08.043.Search in Google Scholar PubMed

24. D’Haens, G, Dubinsky, M, Kobayashi, T, Irving, PM, Howaldt, S, Pokrotnieks, J, LUCENT Study Group, et al.. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2023;388:2444–55. https://doi.org/10.1056/nejmoa2207940.Search in Google Scholar PubMed

25. Steere, B, Schmitz, J, Powell, N, Higgs, R, Gottlieb, K, Liu, Y, et al.. Mirikizumab regulates genes involved in ulcerative colitis disease activity and anti-TNF resistance: results from a phase 2 study. Clin Transl Gastroenterol 2023;14:e00578. https://doi.org/10.14309/ctg.0000000000000578.Search in Google Scholar PubMed PubMed Central

26. Johnson, T, Steere, B, Zhang, P, Zang, Y, Higgs, R, Milch, C, et al.. Mirikizumab-induced transcriptome changes in ulcerative colitis patient biopsies at week 12 are maintained through week 52. Clin Transl Gastroenterol 2023;14:e00630. https://doi.org/10.14309/ctg.0000000000000630.Search in Google Scholar PubMed PubMed Central

27. Dubinsky, MC, Jairath, V, Feagan, BG, Naegeli, AN, Tuttle, J, Morris, N, et al.. Changes in health-related quality of life and associations with improvements in clinical efficacy: a phase 2 study of mirikizumab in patients with ulcerative colitis. BMJ Open Gastroenterol 2023;10:e001115. https://doi.org/10.1136/bmjgast-2023-001115.Search in Google Scholar PubMed PubMed Central

28. Chua, L, Friedrich, S, Zhang, XC. Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase III LUCENT studies. Clin Pharmacokinet 2023;62:1479–91. https://doi.org/10.1007/s40262-023-01281-z.Search in Google Scholar PubMed PubMed Central

29. Dubinsky, MC, Clemow, DB, Hunter, GT, Li, X, Vermeire, S, Hisamatsu, T, et al.. Clinical effect of Mirikizumab treatment on bowel urgency in patients with moderately to severely active ulcerative colitis and the clinical relevance of bowel urgency improvement for disease remission. Crohns Colitis 2022;360:otac044.10.1093/crocol/otac044Search in Google Scholar PubMed PubMed Central

Received: 2024-06-20
Accepted: 2025-11-12
Published Online: 2025-11-27

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Minireview
  3. Mental toughness and athletic performance: a narrative review
  4. Reviews
  5. The role of the urinary microbiome in diabetes-associated UTIs: current understanding and future directions
  6. Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy?
  7. Original Articles
  8. Menopause, estrogen, and GERD: an exploration of symptoms and endoscopic correlations
  9. A study of pulmonary function in hypothyroid female patients of reproductive age group and its correlation with free T3, T4 and TSH
  10. A retrospective observational study to evaluate the association between self-reported binge alcohol drinkers and asthma
  11. Two hours of urine output are a reliable parameter for intravenous furosemide adequacy and the need for doubling dose in acute heart failure: a prospective study
  12. Physiological belching during impedance-pH monitoring: a meal with Coca-Cola provokes a prompt gastroesophageal reaction with increased prandial belching
https://doi.org/10.1515/jbcpp-2024-0102
Keywords for this article
ulcerative colitis; mirikizumab; cytokines; monoclonal antibody

Articles in the same Issue

  1. Frontmatter
  2. Minireview
  3. Mental toughness and athletic performance: a narrative review
  4. Reviews
  5. The role of the urinary microbiome in diabetes-associated UTIs: current understanding and future directions
  6. Interleukin-23 (IL-23) inhibitor, mirikizumab in the treatment of ulcerative colitis (UC): a promising therapy?
  7. Original Articles
  8. Menopause, estrogen, and GERD: an exploration of symptoms and endoscopic correlations
  9. A study of pulmonary function in hypothyroid female patients of reproductive age group and its correlation with free T3, T4 and TSH
  10. A retrospective observational study to evaluate the association between self-reported binge alcohol drinkers and asthma
  11. Two hours of urine output are a reliable parameter for intravenous furosemide adequacy and the need for doubling dose in acute heart failure: a prospective study
  12. Physiological belching during impedance-pH monitoring: a meal with Coca-Cola provokes a prompt gastroesophageal reaction with increased prandial belching
Downloaded on 17.4.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2024-0102/html
Scroll to top button